ASPIRE Haemophilia regional landing page

Pfizer is pleased to announce the 2017 regional ASPIRE competitive research grants programme in haemophilia

Background

The 2017 Regional Advancing Science through Pfizer: Investigator Research Exchange (ASPIRE) Haemophilia Research Awards Programme is a competitive grants programme that reflects the commitment of Pfizer Haemophilia to support ongoing basic science and clinical investigation in haemophilia A and B.

Ongoing basic science research and clinical research are critical to deepen understanding of disease mechanisms and to ensure advancement of management strategies for haemophilia A and haemophilia B and their related co-morbidities. In an era of increased competition for research funding, the 2017 Regional ASPIRE Haemophilia Research Awards Programme is designed to support laboratory and clinical research in pathogenesis, complications, management, and clinical outcomes of haemophilia A and B.

The 2017 ASPIRE Programme is run in 3 phases:

WAVE 1: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK (NOW CLOSED)

WAVE 2: Bulgaria, Croatia, Czech Republic, Hungary, Israel, Kyrgyzstan, Mongolia, Poland, Romania, Serbia, Slovakia, Slovenia, Turkey, Ukraine (NOW CLOSED)

WAVE 3: Young Investigator Award – Europe, Australia, Japan and New Zealand (NOW OPEN)

Mission

  • To support basic science, translational and clinical research through a competitive grants programme that advances medical knowledge in the pathogenesis and treatment of both haemophilia A and B
  • To support academic and professional development

Wave 3 Young Investigator Award Areas of Research Focus

Pfizer will consider proposals for research projects which address one of the following areas in haemophilia A and / or haemophilia B. Applications comprising laboratory investigation or clinical research will be considered
  • Prophylaxis schedules / Individualised prophylaxis
  • Pharmacokinetics
  • Laboratory measurement
  • Joint assessment
  • Patient-reported outcomes
  • Cost of care

Wave 3 Application and Selection Process

Selection of research proposals will be performed by an independent, external expert panel composed of established academic clinicians. Wave 3 application is open to investigators (under 35 years of age) from the following countries: Australia, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, Kyrgyzstan, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Mongolia, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK, Ukraine

PP-GIP-EUR-1106
Date of preparation: November 2017